Sciensus
UK business
Sciensus Pharma Services Limited is a global life sciences business established in 1992 by founder and former chairman Charles Walsh based in London.
The company supplies a wide range of specialist medications and patient support programmes for chronic, cancer and rare disease patients, with around 1,600 employees dealing with more than 230,000 patients a year. It works with every NHS trust in the UK.
In Spring 2015, Healthcare at Home reverted to using in house logistics rather than working with a third party for all deliveries.
In Autumn 2015, the company went through a full corporate rebranding, including new logos, literature, strap line and website in an attempt to re-establish the company's status in the market.
The company's name was changed in 2022 from "Healthcare at Home LTD" to "Sciensus Pharma Limited", using only "Sciensus" to refer to themselves from then on.
In July 2023, 1 patient died and 3 were hospitalised after being administered unlicensed versions of cabazitaxel chemotherapy provided by Sciensus. This follows reports in May 2023 of complaints of poor service and delays raised about the company, sparking a possible CQC review. This resulted in "partial suspension" of its licence by the Medicines and Healthcare products Regulatory Agency (MHRA).
History
In 2013 Healthcare at Home took over almost 3,000 patients from another drug delivery company, Medco Health Solutions which pulled out of the UK market. Subsequently, the company struggled to maintain services.
Begin with the source’s own compact description: “Sciensus” is uK business. The dossier treats that line as a proposition to test through Sciensus and business, not as a finished interpretation.
Why this record matters
The phrase “uK business” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jun 15, 2026. The linked authority identifier is Q17264483. None of the 1 selected statements returned an explicit reference. The first chronological checks are 1992, 2015, 2022 and 2023.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Sciensus”, its source revision and the description used here.
- Expand the search: follow Sciensus primary sources, Sciensus archive and Sciensus research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Sciensus”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Sciensus” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.